Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 24

Results For "API"

2692 News Found

Takeda exits cell therapy research
R&D | October 05, 2025

Takeda exits cell therapy research

Takeda will seek an external partner to leverage its cell therapy platform technologies


Supriya Lifescience’s Ambernath facility receives WHO GMP certification
News | October 04, 2025

Supriya Lifescience’s Ambernath facility receives WHO GMP certification

With global certification in place, the Ambernath site expands Supriya’s footprint beyond APIs into high-margin formulations


Lupin launches Liraglutide injection in US
News | October 04, 2025

Lupin launches Liraglutide injection in US

Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk


A. P. Rameswara Rao appointed National President of BDMAI
People | October 03, 2025

A. P. Rameswara Rao appointed National President of BDMAI

A Post Graduate in Science faculty and has a wide experience spanning over 35 years in the field of manufacturing Bulk Drugs and Active Pharmaceutical Intermediaries


Novartis to launch DTP platform for Cosentyx in US
Supply Chain | October 01, 2025

Novartis to launch DTP platform for Cosentyx in US

Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers


Pfizer agrees to slash prescription drug prices for Americans
News | October 01, 2025

Pfizer agrees to slash prescription drug prices for Americans

Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%


AbbVie begins construction of $70 million biologics manufacturing site in US
News | October 01, 2025

AbbVie begins construction of $70 million biologics manufacturing site in US

The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology


AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer
Drug Approval | October 01, 2025

AbbVie seeks FDA approval for Pivekimab Sunirine to treat rare, aggressive blood cancer

BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma